{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T17:35:20Z","timestamp":1793208920727,"version":"4.5.0"},"reference-count":24,"publisher":"Oxford University Press (OUP)","issue":"4","license":[{"start":{"date-parts":[[2026,2,21]],"date-time":"2026-02-21T00:00:00Z","timestamp":1771632000000},"content-version":"vor","delay-in-days":1,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"BridgeBio Pharma Inc., San Francisco, CA, USA"},{"name":"Bayer AG, Berlin, Germany"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,10,28]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Aims<\/jats:title>\n                    <jats:p>Acoramidis is an oral transthyretin (TTR) stabilizer that achieves near-complete (\u226590%) TTR stabilization. This post-hoc analysis evaluated response categories based on NT-proBNP concentration and 6-minute walk distance (6MWD) changes among participants with transthyretin amyloid cardiomyopathy (ATTR-CM) in the phase 3 ATTRibute-CM trial.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Clinically meaningful improvement (CMI) was defined as a decrease from baseline to Month 30 in NT-proBNP of &amp;gt;700\u2005ng\/L and &amp;gt;30%, and separately, a 6MWD increase of &amp;gt;35\u2005m.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Data from 611 participants were analysed (409: acoramidis; 202: placebo). Median baseline NT-proBNP and 6MWD values were 2273\u2005ng\/L and 365\u2005m in the acoramidis group and 2274\u2005ng\/L and 352\u2005m in the placebo group, respectively. A significantly higher proportion of participants in the acoramidis group reached CMI in NT-proBNP or 6MWD (22.7%) compared with the placebo group (8.9%; OR 3.0, 95% CI 1.8\u20135.1; P &amp;lt; .001).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Acoramidis led to CMI from baseline in NT-proBNP concentration or 6MWD in a considerable proportion of participants with ATTR-CM. These findings suggest that the treatment paradigm of ATTR-CM may evolve from slowing disease progression to achieving improvement.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/ejhf\/xuag048","type":"journal-article","created":{"date-parts":[[2026,2,19]],"date-time":"2026-02-19T12:57:47Z","timestamp":1771505867000},"page":"779-786","source":"Crossref","is-referenced-by-count":5,"title":["Impact of acoramidis on clinical stability in transthyretin amyloid cardiomyopathy: observations from ATTRibute-CM"],"prefix":"10.1093","volume":"28","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1622-0732","authenticated-orcid":false,"given":"Francesco","family":"Cappelli","sequence":"first","affiliation":[{"name":"Tuscan Regional Amyloidosis Centre, Department of Clinical and Experimental Medicine, Careggi University Hospital , Largo Brambilla, 3, Florence , , 50134","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marianna","family":"Fontana","sequence":"additional","affiliation":[{"name":"National Amyloidosis Centre, University College London , London ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5470-2257","authenticated-orcid":false,"given":"Pablo","family":"Garcia-Pavia","sequence":"additional","affiliation":[{"name":"Department of Cardiology of Hospital Universitario Puerta de Hierro Majadahonda, Instituto Investigaci\u00f3n Sanitaria Puerta de Hierro, Centro de Investigaci\u00f3n Biom\u00e9dica en Red Enfermedades Cardiovasculares and Centro Nacional de Investigaciones Cardiovasculares , Madrid ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel P","family":"Judge","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Department of Medicine, Medical University of South Carolina , Charleston, SC ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7468-700X","authenticated-orcid":false,"given":"Laura","family":"Obici","sequence":"additional","affiliation":[{"name":"Amyloidosis Research and Treatment Center, Fondazione IRCCS Policlinico San Matteo , Pavia ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6390-6526","authenticated-orcid":false,"given":"Ahmad","family":"Masri","sequence":"additional","affiliation":[{"name":"Division of Cardiovascular Medicine, School of Medicine, Oregon Health & Science University , Portland, OR ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kai","family":"Vogtl\u00e4nder","sequence":"additional","affiliation":[{"name":"Medical Affairs Statistics, Bayer AG , Wuppertal ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Ciaccia","sequence":"additional","affiliation":[{"name":"Global Medical Affairs and Evidence, Bayer Inc , Mississauga, ON ,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0946-3071","authenticated-orcid":false,"given":"Ana","family":"Zazula","sequence":"additional","affiliation":[{"name":"Clinical Development & Operations, Bayer , Sao Paulo ,","place":["Brazil"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Fran\u00e7ois","family":"Tamby","sequence":"additional","affiliation":[{"name":"Clinical Development, BridgeBio Pharma, Inc. , San Francisco, CA ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam","family":"Casta\u00f1o","sequence":"additional","affiliation":[{"name":"Clinical Development, BridgeBio Pharma, Inc. , San Francisco, CA ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan C","family":"Fox","sequence":"additional","affiliation":[{"name":"Clinical Development, BridgeBio Pharma, Inc. , San Francisco, CA ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steen H","family":"Poulsen","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Aarhus University Hospital , Aarhus ,","place":["Denmark"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4058-3848","authenticated-orcid":false,"given":"Thibaud","family":"Damy","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Referral Center for Cardiac Amyloidosis, H\u00f4pital Henri-Mondor , Cr\u00e9teil ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James L","family":"Januzzi","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Department of Medicine, Massachusetts General Hospital, Harvard Medical School , Boston, MA ,","place":["USA"]},{"name":"Harvard Medical School, Baim Institute for Clinical Research , Boston, MA ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julian D","family":"Gillmore","sequence":"additional","affiliation":[{"name":"National Amyloidosis Centre, University College London , London ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,2,20]]},"reference":[{"key":"2026102813065216900_xuag048-B1","volume-title":"Transthyretin Amyloid Cardiomyopathy (ATTR-CM)","author":"Jain","year":"2025"},{"key":"2026102813065216900_xuag048-B2","doi-asserted-by":"publisher","first-page":"898","DOI":"10.1056\/NEJM199709253371306","article-title":"The systemic amyloidoses","volume":"337","author":"Falk","year":"1997","journal-title":"N Engl J Med"},{"key":"2026102813065216900_xuag048-B3","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1161\/CIRCULATIONAHA.118.038169","article-title":"Natural history, quality of life, and outcome in cardiac transthyretin amyloidosis","volume":"140","author":"Lane","year":"2019","journal-title":"Circulation"},{"key":"2026102813065216900_xuag048-B4","doi-asserted-by":"publisher","first-page":"e7","DOI":"10.1161\/cir.0000000000000792","article-title":"Cardiac amyloidosis: evolving diagnosis and management: a scientific statement from the American Heart Association","volume":"142","author":"Kittleson","year":"2020","journal-title":"Circulation"},{"key":"2026102813065216900_xuag048-B5","doi-asserted-by":"publisher","first-page":"7862","DOI":"10.1021\/acs.jmedchem.8b00817","article-title":"Enthalpy-driven stabilization of transthyretin by AG10 mimics a naturally occurring genetic variant that protects from transthyretin amyloidosis","volume":"61","author":"Miller","year":"2018","journal-title":"J Med Chem"},{"key":"2026102813065216900_xuag048-B6","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1007\/s11897-025-00701-4","article-title":"Etiological treatment of cardiac amyloidosis: standard of care and future directions","volume":"22","author":"Ferrari Chen","year":"2025","journal-title":"Curr Heart Fail Rep"},{"key":"2026102813065216900_xuag048-B7","author":"U.S. Food and Drug Administration"},{"key":"2026102813065216900_xuag048-B8","author":"European Medicines Agency"},{"key":"2026102813065216900_xuag048-B9","author":"Pharmaceuticals and Medical Devices Agency"},{"key":"2026102813065216900_xuag048-B10","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1056\/NEJMoa2305434","article-title":"Efficacy and safety of acoramidis in transthyretin amyloid cardiomyopathy","volume":"390","author":"Gillmore","year":"2024","journal-title":"N Engl J Med"},{"key":"2026102813065216900_xuag048-B11","doi-asserted-by":"publisher","first-page":"1003","DOI":"10.1016\/j.jacc.2024.11.042","article-title":"Efficacy of acoramidis on all-cause mortality and cardiovascular hospitalization in transthyretin amyloid cardiomyopathy","volume":"85","author":"Judge","year":"2025","journal-title":"J Am Coll Cardiol"},{"key":"2026102813065216900_xuag048-B12","doi-asserted-by":"publisher","first-page":"e012112","DOI":"10.1161\/circheartfailure.124.012112","article-title":"Changing treatment landscape in transthyretin cardiac amyloidosis","volume":"18","author":"Fontana","year":"2025","journal-title":"Circ Heart Fail"},{"key":"2026102813065216900_xuag048-B13","doi-asserted-by":"publisher","first-page":"1276","DOI":"10.1016\/j.jacc.2023.12.036","article-title":"Stratifying disease progression in patients with cardiac ATTR amyloidosis","volume":"83","author":"Ioannou","year":"2024","journal-title":"J Am Coll Cardiol"},{"key":"2026102813065216900_xuag048-B14","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/j.jacc.2024.04.011","article-title":"Prognostic value of a 6-minute walk test in patients with transthyretin cardiac amyloidosis","volume":"84","author":"Ioannou","year":"2024","journal-title":"J Am Coll Cardiol"},{"key":"2026102813065216900_xuag048-B15","doi-asserted-by":"publisher","first-page":"1943","DOI":"10.1016\/j.jacc.2025.03.454","article-title":"Impact of vutrisiran on functional capacity and quality of life in transthyretin amyloidosis with cardiomyopathy","volume":"85","author":"Sheikh","year":"2025","journal-title":"J Am Coll Cardiol"},{"key":"2026102813065216900_xuag048-B16","author":"Zhang"},{"key":"2026102813065216900_xuag048-B17","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1097\/01823246-201324030-00004","article-title":"Clinically meaningful change estimates for the six-minute walk test and daily activity in individuals with chronic heart failure","volume":"24","author":"Shoemaker","year":"2013","journal-title":"Cardiopulm Phys Ther J"},{"key":"2026102813065216900_xuag048-B18","author":"Alexander"},{"key":"2026102813065216900_xuag048-B19","doi-asserted-by":"publisher","first-page":"e012135","DOI":"10.1161\/CIRCHEARTFAILURE.124.012135","article-title":"Effect of acoramidis on myocardial structure and function in transthyretin amyloid cardiomyopathy: insights from the ATTRibute-CM cardiac magnetic resonance (CMR) substudy","volume":"17","author":"Razvi","year":"2024","journal-title":"Circ Heart Fail"},{"key":"2026102813065216900_xuag048-B20","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1161\/CIRCULATIONAHA.124.072771","article-title":"Long-term efficacy and safety of acoramidis in ATTR-CM: initial report from the open-label extension of the ATTRibute-CM trial","volume":"151","author":"Judge","year":"2025","journal-title":"Circulation"},{"key":"2026102813065216900_xuag048-B21","doi-asserted-by":"publisher","first-page":"1657","DOI":"10.1161\/circulationaha.122.060852","article-title":"Impact of earlier diagnosis in cardiac ATTR amyloidosis over the course of 20 years","volume":"146","author":"Ioannou","year":"2022","journal-title":"Circulation"},{"key":"2026102813065216900_xuag048-B22","doi-asserted-by":"publisher","first-page":"999","DOI":"10.1093\/eurheartj\/ehae811","article-title":"Transthyretin amyloid cardiomyopathy: a paradigm for advancing precision medicine","volume":"46","author":"Gonzalez-Lopez","year":"2025","journal-title":"Eur Heart J"},{"key":"2026102813065216900_xuag048-B23","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1002\/ejhf.2198","article-title":"Expert consensus on the monitoring of transthyretin amyloid cardiomyopathy","volume":"23","author":"Garcia-Pavia","year":"2021","journal-title":"Eur J Heart Fail"},{"key":"2026102813065216900_xuag048-B24","doi-asserted-by":"publisher","first-page":"3250","DOI":"10.1002\/ehf2.14542","article-title":"Relationship of atrial fibrillation and N terminal pro brain natriuretic peptide in heart failure patients","volume":"10","author":"Nasab Mehrabi","year":"2023","journal-title":"ESC Heart Fail"}],"container-title":["European Journal of Heart Failure"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/eurjhf\/advance-article-pdf\/doi\/10.1093\/ejhf\/xuag048\/67061384\/xuag048.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/eurjhf\/article-pdf\/28\/4\/779\/67061384\/xuag048.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/eurjhf\/article-pdf\/28\/4\/779\/67061384\/xuag048.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T17:06:59Z","timestamp":1793207219000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/eurjhf\/article\/28\/4\/779\/8494232"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,20]]},"references-count":24,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2026,2,20]]},"published-print":{"date-parts":[[2026,10,28]]}},"URL":"https:\/\/doi.org\/10.1093\/ejhf\/xuag048","relation":{},"ISSN":["1388-9842","1879-0844"],"issn-type":[{"value":"1388-9842","type":"print"},{"value":"1879-0844","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,4]]},"published":{"date-parts":[[2026,2,20]]}}}